BC Innovations | Mar 25, 2010
Targets & Mechanisms

SK channel activation for alcoholism

Researchers at the Ernest Gallo Clinic and Research Center at University of California, San Francisco have found that activating small conductance calcium-activated potassium channels in the nucleus accumbens region of the brain could help treat...
BioCentury | Jan 9, 2006
Finance

Post-launch report

Post-launch report Company Product Indication 2004 approval 2005 9-mo sales Anika (ANIK)/J&J (JNJ) Orthovisc Pain from osteoarthritis of the knee U.S. $6.0 Anormed (TSX:AOM)/Shire (LSE:SHP; SHPGY) Fosrenol High blood phosphate levels in end-stage renal disease...
BC Week In Review | Apr 25, 2005
Clinical News

Acamprosate calcium neurology data

A pooled analysis from five 1-year, double-blind, placebo-controlled trials in 1,681 patients showed that the overall incidence of spontaneously reported adverse events was similar between the 1,998 mg daily Campral arm and the placebo arm....
BC Week In Review | Apr 25, 2005
Clinical News

Acamprosate calcium: Post-marketing study data

A pooled analysis of various studies in 3,395 subjects showed that the incidence of adverse events in patients treated with Campral concomitantly with medications such as antidepressants, anxiolytics, sedatives, hypnotics and analgesics were comparable to...
BC Week In Review | Jan 17, 2005
Company News

Forest Laboratories sales and marketing update

FRX launched its Campral acamprosate delayed-released tablets to treat alcohol dependence in patients who are abstinent from alcohol at treatment initiation. Campral is partnered with Merck KGaA (FSE:MRK, Darmstadt, Germany) and received FDA approval in...
BC Extra | Jan 11, 2005
Company News

Forest launches Campral

FRX launched its Campral acamprosate delayed-released tablets to treat alcohol dependence in patients who are abstinent from alcohol at treatment initiation. Campral is partnered with Merck KGaA (FSE:MRK) and received FDA approval in July 2004....
BioCentury | Jan 10, 2005
Finance

New product sales to watch

New product sales to watch Company Product Indication 2004 approval Amgen/NPS Sensipar (Mimpara - EU) Secondary hyperparathyroidism, elevated calcium in parathyroid cancer U.S./EU Amgen Kepivance Severe oral mucositis U.S. Anika/J&J Orthovisc Pain from osteoarthritis of the...
BioCentury | Dec 20, 2004
Strategy

Alkermes: Looking to break out

While drug delivery has often been portrayed as an easy route to company-building, in general the promise has exceeded the reality. Alkermes Inc. believes it will be an exception, which will be witnessed by its...
BC Extra | Oct 18, 2004
Financial News

Forest beats Street

FRX posted fiscal second quarter EPS of $0.79, beating the Street by $0.03 and up 61% up from $0.49 in the same quarter last year. Before FRX pre-announced strong earnings earlier this month, the Street...
BioCentury | Oct 4, 2004
Finance

3Q approvals/3Q setbacks

3Q approvals/3Q setbacks 3Q approvals Selected third quarter product approvals. Company Approval Cellegy (CLGY) U.K. approves Rectogesic (Cellegesic) to treat pain associated with chronic anal fissures Forest (FRX) FDA approves Campral acamprosate to treat alcohol...
Items per page:
1 - 10 of 13